YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)
Duragesic Patch
Injured by the Duragesic Patch?
Keywords: Duragesic | Lawyer | Death | Attorney | Injury | Overdose | Lawsuit
On July 15, 2005 the FDA issued a Public Health Advisory concerning the use of Duragesic Patches (Fentanyl transdermal) in response to reports of deaths in patients using the patch. The FDA is conducting an investigation into the deaths associated with these patches. Our Dedicated Lawyers and Attorneys Have Years of Experience
Handling Defective Drug Lawsuits Such as Duragesic!
Handling Defective Drug Lawsuits Such as Duragesic!
The Agency has been examining the circumstances of product use to determine if the reported adverse events may be related to inappropriate use of the patch or factors related to the quality of the product. It is possible that some patients and their health care providers may not be completely aware of the dangers of these potent narcotic drug products and the important recommendations regarding their safe use.
There has been an expanded recall of Duragesic Patches due to possible leaks. Janssen Pharmaceutica, the manufacturer of the Duragesic Patch notified healthcare professionals of an expanded recall of the Duragesic 75 mcg/h, in February 2004. Four additional lots have been subject to the present expanded recall. Some patches from the recalled lots may leak medication due to improper sealing of one of their edges.
Once You Fill Out The Duragesic Case Review Form, One of Our
Lawyers Skilled In Defective Drug Litigation Will Contact You.
Lawyers Skilled In Defective Drug Litigation Will Contact You.
If the medication leaks out of the patch, exposure to the medication can result in inadvertent ingestion or increased transdermal absorption of the active opiate component fentanyl, leading to potentially life-threatening complications. In addition, leakage of the medication could lead to inadequate dosing, resulting in treatment failure and/or opiate withdrawal.
The Duragesic Patch is indicated for the management of severe, chronic pain (such as cancer pain) that cannot be managed with less powerful drugs such as acetaminophen-opioid combinations and nonsteroidal analgesics.
Moreover, only patients who are already on and tolerant to opioid therapy, and require continuous opioid administration should use the patch. Approved by the U.S. Food and Drug Administration (FDA) in 1990, the Duragesic patch releases fentanyl, a strong opioid, through the skin at a fixed rate for 72 hours. The patch is available only by prescription.
If you or a loved one used a Duragesic Patch and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects lawyer / attorney.
Duragesic PatchRSS Feed
Actavis Recalls More Fentanyl Pain Patches
Mar 3, 2008 | Parker Waichman Alonso LLP
More Fentanyl Pain Patches have been recalled by Actavis Inc due to a possible defect that could cause fentanyl to leak from the Actavis pain patches. Actavis had recalled 14 lots of the Fentanyl Pain Patches in mid-February. Actavis said the remaining lots of the fentanyl transdermal system patches are being recalled as a precautionary measure because the company lacks insurance that all patches are free from defectsFentanyl transdermal patches are indicated for the...
Another Fentanyl Pain Patch Recall
Feb 18, 2008 | Parker Waichman Alonso LLP
Another fentanyl pain patch has been recalled today, amid concerns that such pain patches put users at risk of accidental fentanyl overdose. Today’s fentanyl pain patch recall was issued by Activis Inc., which is recalling 14 lots of its Fentanyl transdermal system CII patches sold in the United States by its subsidiary Actavis South Atlantic LLC from wholesalers and pharmacies as a precaution. The recalled patches were manufactured by Corium International Inc., a...
Duregesic Patch Recall Adds to Johnson & Johnson Patch Woes
Feb 13, 2008 | Parker Waichman Alonso LLP
The Duragesic Pain Patch has been recalled by Johnson & Johnson because defects in the manufacture of the patch could lead to accidental overdoses. Johnson & Johnson is recalling about 32 million of the fentanyl-containing Duragesic Pain Patches, and the company estimates that about two out of every million patches could be defective. The Duragesic and other similar pain patches are meant to treat persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age or...
Duragesic Pain Patch, Other Fentanyl Pain Patches Still Killing People, FDA Warns
Dec 21, 2007 | Parker Waichman Alonso LLP
The Duragesic patch and other generic fentanyl pain patches are still killing people, the Food & Drug Administration (FDA) warned today. The Duragesic pain patch, marketed by Johnson & Johnson, and other generic pain patches, emit the powerful narcotic painkiller fentanyl. These transdermal pain patches were approved to treat pain in people who use narcotics, such as cancer patients. Today’s FDA notice is the second time since 2005 that the agency has warned of...
Johnson & Johnson Settles Duragesic Patch Wrongful Death Lawsuit for $2.5 Million
Jul 30, 2007 | Parker Waichman Alonso LLP
Johnson & Johnson has agreed to settle wrongful death claims involving its Duragesic pain-killing patch for more than $2.5 million, according to Bloomberg.com. The settlement, paid to the family of a Florida man who overdosed on the opiod painkiller fentanyl while wearing the patch in 2003, was the first awarded by Johnson & Johnson in a case involving the Duragesic patch. Hundreds more wrongful death suits are still in the works.“The settlement indicates that Johnson...
Duragesic Patch
Duragesic Patch FDA Info
FDA Drug Information Facts
DURAGESIC PATCH ( Fentanyl Transdermal ) FDA INFORMATION
The FDA issued several warnings concerning Duragesic Patch related side effects. The links below will redirect you to these warnings on the FDA website.
Quick Facts
Duragesic Patch Reference Guide
Date Approved
1990
Manufacturer
Janssen
Status
2/2004 Recall
7/ 2005 Health Advisory
Approved Uses
Pain management
Complications
Death
Possible leaks
Inadvertent ingestion
Related Topics
Oxycontin
Defective Drugs
1990
Manufacturer
Janssen
Status
2/2004 Recall
7/ 2005 Health Advisory
Approved Uses
Pain management
Complications
Death
Possible leaks
Inadvertent ingestion
Related Topics
Oxycontin
Defective Drugs
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS
